Treatment for Churg-Strauss Syndrome: Induction of Remission and Efficacy of Intravenous Immunoglobulin Therapy  by Taniguchi, Masami et al.
Allergology International Vol 56, No2, 2007 www.jsaweb.jp 97
Treatment for Churg-Strauss
Syndrome: Induction of Remission
and Efficacy of Intravenous
Immunoglobulin Therapy
Masami Taniguchi1, Naomi Tsurikisawa1, Noritaka Higashi1, Hiroshi Saito1, Haruhisa Mita1,
Akio Mori1, Hiroki Sakakibara2 and Kazuo Akiyama1
ABSTRACT
Churg-Strauss syndrome (CSS) is characterized by the presence of asthma, eosinophilia, and small-vessel
vasculitis with granuloma. It is a distinct entity, as determined from all classifications of systemic vasculitis. The
poor prognostic factors in CSS are renal insufficiency, cardiomyopathy, severe gastrointestinal (GI) tract, and
central nervous systems (CNS) involvement. The initial management of CSS should include a high dose of a
corticosteroid: prednisone at 1 mgkgday or its equivalent for methylprednisolone with tapering over 6
months. In patients with severe or rapidly progressing CSS, the administration of methylprednisolone pulse at
1 gbodyday for 3 days is recommended. When corticosteroid therapy does not induce remission, or when pa-
tients have poor prognostic factors, immunosuppressive cytotoxic therapy is indicated. However, some patients
with severe CSS often show resistance to conventional treatment. We think that IVIG therapy is a hopeful can-
didate for second-line treatment for CSS patients, particularly in the case of neuropathy andor cardiomyopa-
thy, which are resistant to conventional therapy. However, there is not much evidence supporting the effective-
ness of IVIG in CSS, and the mechanisms underlying the action of IVIG remain unclear. Now we are perform-
ing clinical trials of IVIG therapy for CSS patients who are resistant to conventional treatment, through a nation-
wide double-blinded placebo-controlled study in Japan.
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INTRODUCTION
Churg-Strauss syndrome (CSS) is characterized by
the presence of asthma, eosinophilia, and small-
vessel vasculitis with granuloma.1,2 It is a distinct en-
tity, listed separately in the classifications of systemic
vasculitis.2,3 The syndrome was named after the two
pathologists, J. Churg and L. Strauss, who first de-
scribed it in 1951 as a disease that is similar to but
clearly distinct from polyarteritis nodosa (PAN).1
Eosinophilic infiltration andor ischemic damage due
to vasculitis are often detected in the lungs, skin, GI
tract, heart, and peripheral neurons.1-7
In 1990, the American College of Rheumatology
(ACR) proposed six classification criteria for CSS (Ta-
ble 1).8 CSS is one of typical members of anti-
neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis, that also include Wegener’s granulomato-
sis (WG) and microscopic polyangitis (MPA), and
clearly distinct from classical PAN, which involves
medium-sized arteries and is usually not associated
with ANCA. The type of ANCA in CSS is mainly anti-
myeloperoxydase (MPO) antibody, which is also
common in MPA.
The natural history of CSS is, first, the appearance
of eosinophilic rhinosinusitis, followed several years
later by the development of severe asthma with
marked peripheral blood eosinophilia, and finally the
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Table 1 1990 American Colege of Rheumatology Criteria for the Classification of Churg-Strauss Syndrome
DefinitionCriterion
History of wheezing or difuse, high-pitched rales on expiration1. Asthma 
Eosinophilia＞ 10% of white blood cel diferential count2. Eosinophilia 
Development of mononeuropathy, multiple mononeuropathies, or polyneuropathy 
(i.e., glove/stocking distribution) atributable to vasculitis
3. Mononeuropathy or polyneuropathy 
Migratory or transitory pulmonary infiltrates on radiographs (not including fixed infil-
trates), atributable to systemic vasculitis
4. Pulmonary infiltrates, nonfixed 
History of acute or chronic paranasal sinus pain or tenderness, or radiographic opa-
cification of the paranasal sinuses
5. Paranasal sinus abnormality 
Biopsy including artery, arteriole or venule, showing accumulations of eosinophils in 
extravascular areas
6. Extravascular eosinophils
For classification purposes, a patient with vasculitis shal be said to have Churg-Strauss syndrome if at least four of these six criteria 
are present.
The presence of any four or more criteria yields a sensitivity of 85% and a specificity of 99.7%. (Adapted from Masi et al.8)
development of systemic vasculitis. In the series of
patients studied by Guillevin et al., 97.9% of the pa-
tients had asthma and 37.5% had pulmonary infiltrates
on chest X-ray.3
Various CSS therapies can markedly alter the
course of CSS: 50% or fewer of those who are un-
treated die within 3 months of diagnosis, whereas
treated patients have a 10-year survival rate of more
than 70%. Many CSS patients respond rapidly to corti-
costeroids. With treatment, remission is obtained in
more than 80% of CSS patients.4 However, patients
with moderate to severe CSS do not respond to corti-
costeroids well. Cardiac involvement is the primary
cause of death of CSS patients,1-3,9-11 who do not fully
respond to conventional treatment. Moreover, almost
all CSS patients show long-lasting and steroid-
resistant neuralgia and muscle weakness due to pe-
ripheral neuropathy.
In this article, we review the recent reports on the
management of CSS and the induction remission and
efficacy of intravenous immunoglobulin therapy.
PROGNOSTIC FACTORS
The outcome of CSS depends on the extent of disease
dissemination and the severity of visceral involve-
ment. In a prospective study of 342 patients with CSS
or PAN, Guillevin et al. evaluated several clinical, bio-
logical, immunological, and therapeutic factors and
identified poor prognostic factors, namely, protein-
uria, renal insufficiency, cardiomyopathy, and severe
GI tract involvement.9 Moreover, previous reports
showed that old age and CNS involvement are also
poor prognostic factors.3,10 The majority of CSS pa-
tients without these factors show a good response to
corticosteroids and survive for a long time.
CONVENTIONAL TREATMENT OF CSS
CORTICOSTEROIDS
CSS patients respond rapidly to corticosteroids, but
sometimes they must be administered together with
cytotoxic agents, which are useful for patients with
severe CSS. The initial management of CSS should
include a high dose of corticosteroid: prednisone at 1
mgkgday, or its equivalent for methylprednisolone
with tapering over 6 months. In patients with severe
or rapidly progressing CSS, the administration of
methylprednisolone pulse at 1 gbodyday for 3 days
is recommended.3,6,7 Corticosteroids are often highly
effective and clinical symptoms and eosinophilia im-
proves dramatically. Vasculitis remission is obtained
in most patients with mild to moderate CSS with cor-
ticosteroids alone (Table 2). After the improvement
of clinical symptoms and the normalization of blood
parameters (ESR, CRP, LDH, CK, ANCA titer and
eosinophil count), the tapering of the prednisone
dose can begin. The tapering of prednisone is as fol-
lows: 10 to 15% decrease at one- to two-week inter-
vals with monitoring of peripheral eosinophilia and
clinical symptoms. In the stable condition and remis-
sion stage after an intensive therapy, CSS in the ma-
jority patients can be controlled with low doses of
prednisone (mean dose: 8.85 ± 6.8 mgday), together
with inhaled corticosteroid.10
CYTOTOXIC AGENTS
Asthma symptoms, pulmonary infiltration, and skin
lesions are usually resolved after corticosteroid ther-
apy. Although most CSS patients respond well to cor-
ticosteroid therapy, some organ impairments are not
easily resolved; cardiac, GI, and neurological involve-
ment do not respond well to treatment with a corti-
costeroid alone. Moreover, from our experience, pa-
tients with moderate to severe CSS, or CSS patients
with prominent peripheral neuropathy, such as gait
disturbance, often show resistance to treatment with
corticosteroids alone.
When corticosteroid therapy does not induce re-
mission, or when patients have a poor prognostic fac-
tor such as cardiac, GI, renal, or CNS involvement,
immunosuppressive cytotoxic therapy is indicated.
Patients with systemic vasculitis syndrome, including
those with WG and MPA, respond well to cytotoxic
Treatment of CSS with IVIG
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Table 2 Summary of treatment options for Churg-Strauss vasculitis
CommentsDoseIndicationsTreatmentDiagnosis
Corticosteroid monother-
apy controls most pa-
tients’ symptoms acutely 
but only rarely induces 
lifelong remission 
1 mg/kg with taper over 
3-6 mo
First-line therapyCorticosteroidsChurg-Strauss 
vasculitis
Monthly intravenous ad-
ministration is beter tol-
erated, no diference in 
survival but decreased 
incidence  of  relapse 
with addition of cyclo-
phosphamide
Monthly intravenous or 
daily oral
In addition to corticoster-
oids for treatment of 
refractory disease, re-
lapse, or acute dis-
ease with involvement 
of ＞＿ 2 extrapulmonary 
organs
Cyclophosphamide
Litle published data, high 
rate of relapse with 
methotrexate
Escalate dose as toler-
ated based on side ef-
fects
Consider as alternative 
corticosteroid-sparing 
agents for maintenance 
therapy, treatment of 
relapse, or both 
Other cytotoxic agents 
(including azathioprine, 
methotrexate)
Litle data to support use in
 CSS, leukoencephalopathy 
reported in 2/12 pa-
tients treated with long-
term IFN-α
NAConsider as alternative 
corticosteroid-sparing 
agents for maintenance 
therapy, treatment of 
relapse, or both 
Immunomodulatory 
agents (including IFN-
α, mycophenolate mof-
etil, TNF blockers, and 
IVIG) 
No published data in CSS 
and uncertain eficacy 
for the underlying vas-
culitis, anti-IgE therapy 
reduces exacerbations 
and symptoms in se-
vere asthma 
NAUnknownmAbs (including anti-IL-
5,anti-IgE
[omalizumab])
Leukotriene modifier use 
in CSS is controversial, 
although data to date 
do not support a causa-
tive role  for  these 
agents in the develop-
ment of CSS
VariableShould be used as adju-
vant therapy in al pa-
tients   with  asthma 
symptoms
Routine asthma manage-
ment
IVIG, Intravenous immunoglobulin; NA, not applicable. (Adapted from Kilon et al.7)
therapy included in the standard regimen.12 The stan-
dard treatment for severe CSS includes cyclophos-
phamide at various dosages is continued for 6 months
to 1 year during remission (Table 2). Oral administra-
tion of cyclophosphamide (2 mgkgday) was previ-
ously reported. However recently, monthly intrave-
nous pulse cyclophosphamide (400―800 mgbody
day) has been used for the treatment of CSS and has
been found to be better tolerated. The most effective
route of cyclophosphamide administration has not
been confirmed.3,6,7 However, from our experience,
intravenous cyclophosphamide pulse often shows
dramatic effect in CSS patients. Guillevin et al. also
recommended intravenous cyclophosphamide pulse
in their review article. Other cytotoxic agents, which
include methotrexate or azathioprine, may be used;
however, they may not be as efficient as cyclophos-
phamide in inducing remission. Remission rate
within 1 year is about 90% to 95%. A small percentage
(5% to 6%) of patients show no response to conven-
tional therapy (corticosteroid and cyclophos-
phamide), and the overall mortality rate in CSS pa-
tients is 20% to 25% over 5 to 10 years.4,10
OTHER TREATMENT OPTIONS
IMMUNOMODULATORY AGENTS
When CSS patients are resistant to corticosteroid and
cyclophophamide, or when patients are unable to ef-
fectively taper the corticosteroid dose, several immu-
nomodulatory agents might be effective.
Intravenous Immunoglobulin (IVIG)
Over the past 20 years, the intravenous administra-
tion of exogenous pooled human immunoglobulin
has become an important therapy in clinical medi-
cine.13 Intravenous administration of a high dose of
human immunoglobulin (IVIG) has shown beneficial
results in some autoimmune diseases and inflamma-
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Fig. 1 Manual muscle test. Before therapy indicates be-
fore treatment with corticosteroids with or without cyclophos-
phamide; IVIG, intravenous high-dose immunoglobulin 
therapy. Bars and boxes represent the mean ± SD. 
(Adapted from Tsurikisawa et al.22)
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Fig. 2 Ejection fraction of echocardiography. IVIG, intrave-
nous high-dose immunoglobulin therapy. Bars and boxes 
represent the mean ± SD. (Adapted from Tsurikisawa et 
al.22)
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Table 3 Immunomodulatory activities of IVIG
Alterations in the populations of lymphocytes in the circulation and in lymphoid tissues1.
Inhibition of lymphocyte (and other leukocyte) activation as determined by proliferation, cytokine production, or expression of 
activation markers (eg, adhesion molecules), mediated by:
2.
a. IVIG interaction with cel surface proteins
b. IVIG binding to cytokines or other soluble mediators
FcγR blockade3.
Induction of inhibitory FcγR4.
Interaction with the complement pathways5.
Idiotype network interactions6.
(Adapted from Binstadt et al.15)
tory disorders, including idiopathic thrombocy-
topenic purpura, Kawasaki disease, and Gullain-Barré
syndrome. The mechanisms underlying the action of
IVIG therapy remain unclear. Some established or
proposed mechanisms of the therapeutic effects of
IVIG therapy are listed in Table 3.14,15
Jayne et al. reported in 1991 that IVIG is effective
in seven patients with ANCA-positive systemic vascu-
litis including WG and MPA.16 Hamilos and Chris-
tensen first reported in 1991 that a 33-year-old man
with CSS, who was resistant to conventional steroid
treatment, showed a marked improvement of vasculi-
tis symptoms and normalization of eosinophil count
after IVIG therapy.17 However, there had been only a
few reports on the use of IVIG therapy for CSS.18-20 In
1994, we encountered a 53-year-old Japanese man
with CSS, who was admitted to Fujita Health Univer-
sity Hospital and complained severe gait disturbance
despite corticosteroid and cyclophosphamide ther-
apy, but showed a marked improvement of neurologi-
cal involvement immediately after the administration
of IVIG.21 Since this experience, we had been at-
tempting to evaluate the efficacy of IVIG therapy in
CSS. In our preliminary study, we were able to con-
firm the efficacy of IVIG therapy particularly on neu-
rological and cardiac involvement in the majority of
patients with CSS who did not respond well to con-
ventional therapy. In 2004, we reported that neuro-
logical and cardiac manifestations in 15 patients with
CSS, who were not responsive to corticosteroids with
or without cyclophosphamide, were significantly im-
proved after IVIG therapy.22 IVIG improved motor
neuropathy within 1 week in 13 of the 15 patients.
The manual muscle strength test showed that IVIG
therapy improved muscle performance, whereas the
conventional treatment before IVIG did not (Fig. 1).22
Cardiac function was improved by IVIG therapy in all
5 patients with heart failure. The ejection fraction of
the left ventricle markedly increased (Fig. 2).22
Treatment of CSS with IVIG
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Fig. 3 The efect of intravenous high-dose immunoglobu-
lin therapy (IVIG) on CD69 ＋ eosinophils. The CD69 cel 
number is expressed in a logarithmic scale. ANOVA, analy-
sis of variance. Bars and boxes represent the mean ± SD. 
(Adapted from Tsurikisawa et al.22)
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Fig. 4 Urinary LTE4 (A) and EDN (B) concentrations in 
each group. Urinary concentrations are expressed by using 
the log scale. Patients with CSS, VD, and RA and HC sub-
jects are denoted by closed squares, closed triangles, open 
triangles, and open circles, respectively. Horizontal bars in-
dicate medians. ＊ P＜ .05; † P＜ .01. HC: healthy 
control, RA: reumatoid arthritis, VD: non-eosinophilic 
vasculitides. (Adapted from Higashi et al.29)
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Eosinophils in the peripheral blood composed less
than 10% of the white blood cell count after the ther-
apy with corticosteroids with or without cyclophso-
phamide. IVIG treatment decreased the number of
CD-69-expressing activated eosinophils from 27.5 to
5.9μl (p < .01), whereas the number of peripheral
eosinophils did not change (Fig. 3).22 Recently,
Danieli et al. reported that complete clinical and func-
tional recovery with a long-term remission by IVIG
with plasmapheresis in 18 patients with CSS.23
Takigawa et al. presented that IVIG with conventional
therapy resulted in a significant improvement in one
alveolar hemorrhage patient with severe CSS.24
These results suggest that IVIG therapy may be a
hopeful second-line treatment for CSS patients, par-
ticularly in the case of neuropathy andor cardio-
myopathy, which are resistant to conventional ther-
apy. However, there is not much evidence supporting
the effectiveness of IVIG therapy in CSS, and the
mechanisms underlying the action of IVIG remain un-
clear. Now we are evaluating the mechanisms under-
lying this action and performing clinical trials of IVIG
therapy for CSS patients who are resistant to conven-
tional treatment, through a nationwide double-
blinded placebo-controlled study in Japan.
Interferon-α
INF-α has a beneficial effect on patients with idi-
opathic hypereosinophilic syndrome (HES). INF-α
has been shown to inhibit eosinophil production and
the release of eosinophil cationic protein and
eosinophil-derived neurotoxin. In CSS there have
been several reports on the decrease in eosinophil
count and disease activity in response to IFN-α. A
good clinical response to a high dose of INF-α was
observed in four patients with CSS, but most of them
showed a relapse at the end of the therapy. Skin le-
sions have also been treated successfully with INF-α.
Unfortunately, although INF-α was effective and tol-
erated for the induction of remission, patients fol-
lowed up for more than one year continued to show
relapses. From these results and a recent report on
leukoencephalopathy in 2 of 12 patients with CSS
who received INF-α for four years,25 maintenance
therapy with INF-α for CSS remains controver-
sial.7,13,26
MONOCLONAL ANTIBODIES
A monoclonal antibody to TNF-α has been useful for
rheumatic diseases and other immunological dis-
eases. However, there are few published reports on
antibodies to TNF-α for CSS. The effects of anti-TNF-
Taniguchi M et al.
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α are still unknown.3,6,7
An antibody to IL-5 has been shown to decrease
eosinophil count in the blood and tissue of patients
with HES. Theoretically, the anti-IL-5 antibody might
be a useful additional therapy for CSS patients.3,7 To-
tal serum IgE level is also increased in patients with
CSS in the acute stage. However, there are no reports
of monoclonal antibodies to IL-5 and IgE for CSS.
Recently, Koukoulaki et al. reported that B cell de-
pletion by rituximab (anti-CD 20) was effective in two
patients with refractory CSS.27 In the near future, the
effect of these antibodies on CSS vasculitis should be
evaluated.
PLASMA EXCHANGE
Several studies attempted to confirm the effect of
plasma exchange on systemic vasculitis including
CSS. However, there is no strong evidence that this
treatment is effective for CSS patients.28
BIOMARKER OF DISEASE ACTIVITY
During the active stage or in the relapsing phase, the
levels of common inflammatory markers, namely,
CRP, ESR, WBC, and some acute phase reactants are
elevated. However, these indicators do not corre-
spond to disease activity and are not specific to CSS
patients. Peripheral eosinophil count is one of good
markers of disease activity, but this count easily nor-
malizes in spite of persistent symptoms. Recently, we
have found that urinary leukotriene (U-LT) E4 con-
centration is a good marker in the acute phase of
CSS. U-LTE4 concentration significantly increases in
not only eosinophilic vasculitides, including CSS, but
also noneosinophilic vasculitides (Fig. 4).29 U-LTE4
concentration may be used as a sensitive biomarker
for monitoring physiological events involved in vascu-
litides.
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